S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
NASDAQ:ALZN

Alzamend Neuro Stock Competitors

$2.14
+0.16 (+8.08%)
(As of 12/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.98
$2.25
50-Day Range
$1.90
$3.08
52-Week Range
$1.87
$33.55
Volume
2.35 million shs
Average Volume
3.99 million shs
Market Capitalization
$185.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Alzamend Neuro (NASDAQ:ALZN) Vs. JANX, KRON, AKRO, CPRX, SLN, KDNY, ZGNX, KZR, PRLD, and DYN

Should you be buying Alzamend Neuro stock or one of its competitors? The main competitors of Alzamend Neuro include Janux Therapeutics (JANX), Kronos Bio (KRON), Akero Therapeutics (AKRO), Catalyst Pharmaceuticals (CPRX), Silence Therapeutics (SLN), Chinook Therapeutics (KDNY), Zogenix (ZGNX), Kezar Life Sciences (KZR), Prelude Therapeutics (PRLD), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical preparations" industry.

Alzamend Neuro vs.

Kronos Bio (NASDAQ:KRON) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, community ranking, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Kronos Bio received 5 more outperform votes than Alzamend Neuro when rated by MarketBeat users. However, 100.00% of users gave Alzamend Neuro an outperform vote while only 72.73% of users gave Kronos Bio an outperform vote.

CompanyUnderperformOutperform
Kronos BioOutperform Votes
8
72.73%
Underperform Votes
3
27.27%
Alzamend NeuroOutperform Votes
3
100.00%
Underperform Votes
No Votes

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kronos BioN/AN/A-$88.44 million-$2.32-5.63
Alzamend NeuroN/AN/AN/AN/AN/A

68.3% of Kronos Bio shares are held by institutional investors. Comparatively, 0.3% of Alzamend Neuro shares are held by institutional investors. 31.2% of Kronos Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Alzamend Neuro's return on equity of 0.00% beat Kronos Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Kronos Bio N/A -25.31% -22.86%
Alzamend Neuro N/A N/A N/A

Kronos Bio currently has a consensus price target of $36.00, indicating a potential upside of 175.65%. Alzamend Neuro has a consensus price target of $11.50, indicating a potential upside of 437.38%. Given Alzamend Neuro's higher probable upside, analysts plainly believe Alzamend Neuro is more favorable than Kronos Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kronos Bio
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Alzamend Neuro
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Kronos Bio and Kronos Bio both had 4 articles in the media. Kronos Bio's average media sentiment score of 0.35 beat Alzamend Neuro's score of 0.00 indicating that Kronos Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kronos Bio
0 Very Positive mention(s)
3 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alzamend Neuro
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Kronos Bio and Alzamend Neuro tied by winning 4 of the 8 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Alzamend Neuro (NASDAQ:ALZN) vs. Its Competitors

TypeAlzamend NeuroPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$185.94M$5.81B$4.96B$7.91B
Dividend YieldN/A2.63%2.05%2.56%
P/E RatioN/A16.2722.3123.43
Price / SalesN/A554.222,429.35276.02
Price / CashN/A146.2661.88204.50
Price / BookN/A5.666.156.53
Net IncomeN/A$95.55M$96.04M$154.44M
7 Day Performance9.74%1.10%0.98%2.05%
1 Month Performance-18.01%-14.00%-12.06%-9.37%
1 Year PerformanceN/A5.47%9.29%26.38%

Alzamend Neuro Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JANX
Janux Therapeutics
1.9315 of 5 stars
$17.76
+4.8%
$35.00
+97.1%
N/A$739.03MN/A0.0016Lockup Expiration
KRON
Kronos Bio
2.6598 of 5 stars
$13.06
+6.8%
$36.00
+175.7%
-58.6%$735.89MN/A-5.6363
AKRO
Akero Therapeutics
2.0388 of 5 stars
$21.05
+4.8%
$51.86
+146.4%
-22.8%$734.39MN/A-7.4622
CPRX
Catalyst Pharmaceuticals
2.5 of 5 stars
$7.07
+2.0%
$8.38
+18.5%
+106.1%$729.04M$119.07M18.1374
SLN
Silence Therapeutics
1.825 of 5 stars
$24.35
+4.6%
$99.00
+306.6%
+26.8%$728.75M$5.48M0.0074Positive News
KDNY
Chinook Therapeutics
2.6248 of 5 stars
$16.05
+1.4%
$33.00
+105.6%
+18.3%$723.42M$830K-4.25105
ZGNX
Zogenix
1.9229 of 5 stars
$12.91
+3.8%
$33.67
+160.8%
-39.7%$722.86M$13.64M-2.97218
KZR
Kezar Life Sciences
1.4398 of 5 stars
$14.66
+8.3%
$17.00
+16.0%
+142.3%$720.48MN/A-14.6647High Trading Volume
PRLD
Prelude Therapeutics
2.3331 of 5 stars
$14.76
+6.2%
$44.00
+198.1%
-70.5%$696.89MN/A-6.8368Gap Up
DYN
Dyne Therapeutics
1.3932 of 5 stars
$13.47
+6.4%
N/A-35.0%$694.08MN/A-5.2847Gap Up
AVIR
Atea Pharmaceuticals
2.0331 of 5 stars
$8.25
+5.9%
$27.33
+231.3%
-71.1%$685.60M$48.63M0.0039
CARA
Cara Therapeutics
2.2917 of 5 stars
$12.74
+4.7%
$25.67
+101.5%
-15.1%$681.07M$135.08M26.0080
RDUS
Radius Health
2.1914 of 5 stars
$14.38
+3.3%
$25.00
+73.9%
+0.8%$680.78M$238.65M-8.88310
VBIV
VBI Vaccines
2.325 of 5 stars
$2.60
+15.0%
$7.00
+169.2%
-21.2%$668.99M$1.06M-10.00130High Trading Volume
CELU
Celularity
2.1333 of 5 stars
$5.35
+1.3%
$11.25
+110.3%
N/A$660.53MN/A0.00N/A
LXRX
Lexicon Pharmaceuticals
1.9714 of 5 stars
$4.33
+4.6%
$12.00
+177.1%
+150.3%$644.72M$24M-9.0278Gap Up
TRDA
Entrada Therapeutics
1.5464 of 5 stars
$21.51
+3.5%
$29.00
+34.8%
N/A$642.87MN/A0.00N/AQuiet Period Expiration
ORMP
Oramed Pharmaceuticals
2.0333 of 5 stars
$16.86
+7.6%
$34.25
+103.1%
+297.6%$642.13M$2.70M-21.6212Gap Up
AFMD
Affimed
2.3448 of 5 stars
$6.45
+5.4%
$12.71
+97.1%
-4.7%$633.95M$32.39M-11.73158
BTAI
BioXcel Therapeutics
1.9229 of 5 stars
$22.57
+7.2%
$97.29
+331.0%
-51.4%$631.51MN/A-5.6150Analyst Revision
Gap Up
TBPH
Theravance Biopharma
2.1115 of 5 stars
$8.54
+8.5%
$10.88
+27.3%
-50.5%$629.38M$71.86M-2.48359
AMYT
Amryt Pharma
1.825 of 5 stars
$9.88
+4.5%
$29.50
+198.6%
-28.7%$628.37M$182.61M-20.582,020
ANNX
Annexon
2.0667 of 5 stars
$16.31
+4.1%
$39.00
+139.1%
-34.8%$625.90MN/A-5.3748
COLL
Collegium Pharmaceutical
2.1714 of 5 stars
$18.05
+0.7%
$25.33
+40.4%
-7.5%$623.97M$310.02M6.89234
FULC
Fulcrum Therapeutics
2.2998 of 5 stars
$15.35
+6.1%
$36.33
+136.7%
+22.4%$622.43M$8.82M-6.5373
EGRX
Eagle Pharmaceuticals
2.2514 of 5 stars
$47.62
+2.1%
$51.00
+7.1%
+1.8%$614.97M$187.80M116.15106
VERA
Vera Therapeutics
1.3798 of 5 stars
$28.89
+5.8%
$24.00
+16.9%
N/A$605.77MN/A0.0019
OGI
OrganiGram
1.7098 of 5 stars
$2.00
+6.5%
$4.04
+101.8%
+37.0%$599.69M$62.43M-4.65517
PHAT
Phathom Pharmaceuticals
2.3665 of 5 stars
$19.06
+1.7%
$60.25
+216.1%
-60.7%$598.77MN/A-4.2255
IMGO
Imago BioSciences
1.7048 of 5 stars
$17.80
+8.9%
$32.00
+79.8%
N/A$596.82MN/A0.002,021Gap Up
High Trading Volume
ORIC
ORIC Pharmaceuticals
2.4664 of 5 stars
$15.10
+4.0%
$26.33
+74.4%
-58.4%$594.67MN/A-6.4861
AMTI
Applied Molecular Transport
2.825 of 5 stars
$15.40
+6.3%
$80.33
+421.6%
-49.9%$592.75MN/A-6.8180
THRX
Theseus Pharmaceuticals
2.0095 of 5 stars
$15.19
+0.7%
$25.00
+64.6%
N/A$587.90MN/A0.00N/A
PNT
POINT Biopharma Global
1.4531 of 5 stars
$6.50
+4.3%
$17.75
+173.1%
N/A$585.79MN/A0.00N/AGap Up
High Trading Volume
SIGA
SIGA Technologies
0.7066 of 5 stars
$7.90
+7.2%
N/A+13.5%$585.52M$124.96M39.5042High Trading Volume
ENOB
Enochian Biosciences
0.3333 of 5 stars
$11.03
+7.3%
N/A+279.0%$575.99MN/A0.0010Gap Up
IVA
Inventiva
1.4798 of 5 stars
$13.65
+0.3%
$42.00
+207.7%
+16.0%$556.14M$430K0.0088
EPIX
ESSA Pharma
2.0333 of 5 stars
$12.59
+5.0%
$34.67
+175.4%
+82.7%$553.76MN/A-12.9825Gap Up
KPTI
Karyopharm Therapeutics
2.4067 of 5 stars
$7.26
+7.4%
$14.83
+104.3%
-53.3%$548.47M$108.08M-2.63432
CMRX
Chimerix
2.0381 of 5 stars
$6.24
+3.0%
$18.00
+188.5%
+37.4%$542.02M$5.37M-3.4354
PHAR
Pharming Group
1.0415 of 5 stars
$8.30
+4.7%
N/AN/A$536.54M$212.10M0.00262Analyst Upgrade
Gap Up
ABUS
Arbutus Biopharma
2.0981 of 5 stars
$3.96
+6.3%
$6.90
+74.2%
+0.3%$535.67M$6.91M-4.3577News Coverage
Gap Up
High Trading Volume
ANIP
ANI Pharmaceuticals
2.7881 of 5 stars
$41.87
+4.1%
$68.33
+63.2%
+41.2%$533.93M$208.48M-22.88369Positive News
IMRX
Immuneering
1.6265 of 5 stars
$20.58
+1.9%
$43.67
+112.2%
N/A$533.87MN/A0.002,021Gap Up
PYR
PyroGenesis Canada
0 of 5 stars
$3.01
+2.3%
N/AN/A$514.10M$13.27M60.212,020
SMMT
Summit Therapeutics
1.1331 of 5 stars
$5.24
+4.0%
N/A+5.0%$512.02M$20.17M-6.0980Analyst Report
NKTX
Nkarta
2.3531 of 5 stars
$15.48
+10.7%
$70.80
+357.4%
-68.0%$510.05M$120K-6.2495Gap Up
VERU
Veru
1.9931 of 5 stars
$6.35
+2.7%
$19.40
+205.5%
+89.6%$507.07M$61.26M57.73339Earnings Report
Analyst Revision
Gap Up
OCUL
Ocular Therapeutix
2.0398 of 5 stars
$6.61
+6.5%
$24.00
+263.1%
-66.8%$506.39M$17.40M-3.42181Analyst Report
ICPT
Intercept Pharmaceuticals
2.4093 of 5 stars
$16.95
+4.5%
$29.67
+75.0%
-50.0%$500.82M$312.69M-5.23498Gap Up
This page was last updated on 12/8/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.